dc.contributor.author
Dalmau Obrador, Josep
dc.contributor.author
Graus Ribas, Francesc
dc.date.issued
2020-01-08T13:00:50Z
dc.date.issued
2020-01-08T13:00:50Z
dc.date.issued
2018-03-01
dc.date.issued
2020-01-08T09:16:55Z
dc.identifier
https://hdl.handle.net/2445/147222
dc.description.abstract
Antibody-mediated encephalitides constitute a group of inflammatory brain diseases that are characterized by prominent neuropsychiatric symptoms and are associated with antibodies against neuronal
cell-surface proteins, ion channels, or receptors (Table 1).1
Common clinical features include a change in behavior, psychosis, seizures, memory and cognitive
deficits, abnormal movements, dysautonomia, and a decreased level of consciousness. There are, however, no systemic manifestations other than autonomic dysfunction, and this group of diseases is separable from traditional autoimmune
disorders such as systemic lupus erythematosus, which may affect the nervous
system. Also separate from this group of antibody-mediated encephalitides are
several disorders, some of which are paraneoplastic, such as cerebellar degeneration,2
neuromyelitis optica,3
and stiff-person spectrum diseases,4
that are associated with antibodies against neuronal or glial cell-surface antigens but that are
rarely associated with the aforementioned symptoms.
The antibody-mediated encephalitides occur in persons
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.1056/NEJMra1708712
dc.relation
New England Journal of Medicine, 2018, vol. 378, num. 9, p. 840-851
dc.relation
https://doi.org/10.1056/NEJMra1708712
dc.rights
(c) Massachusetts Medical Society, 2018
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.title
Antibody-Mediated Encephalitis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion